79
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Transforming growth factor-β and breast cancer: Transforming growth factor-β/SMAD signaling defects and cancer

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Transforming growth factor-β (TGF-β) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-β are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative responses are mediated by a signaling system that includes two types of cell surface receptors and intracellular signal transducers, the SMAD proteins. Different molecular mechanisms can lead to loss of antiproliferative TGF-β responses in tumor cells, including mutations in components of the signaling system and inhibition of the SMAD signaling pathway by aberrant activities of various regulatory molecules. Some of these mechanisms will be discussed, with emphasis on their potential involvement in breast tumorigenesis.

          Related collections

          Most cited references101

          • Record: found
          • Abstract: found
          • Article: not found

          TGF-beta signal transduction.

          The transforming growth factor beta (TGF-beta) family of growth factors control the development and homeostasis of most tissues in metazoan organisms. Work over the past few years has led to the elucidation of a TGF-beta signal transduction network. This network involves receptor serine/threonine kinases at the cell surface and their substrates, the SMAD proteins, which move into the nucleus, where they activate target gene transcription in association with DNA-binding partners. Distinct repertoires of receptors, SMAD proteins, and DNA-binding partners seemingly underlie, in a cell-specific manner, the multifunctional nature of TGF-beta and related factors. Mutations in these pathways are the cause of various forms of human cancer and developmental disorders.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Lessons from hereditary colorectal cancer.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.

              About 90 percent of human pancreatic carcinomas show allelic loss at chromosome 18q. To identify candidate tumor suppressor genes on 18q, a panel of pancreatic carcinomas were analyzed for convergent sites of homozygous deletion. Twenty-five of 84 tumors had homozygous deletions at 18q21.1, a site that excludes DCC (a candidate suppressor gene for colorectal cancer) and includes DPC4, a gene similar in sequence to a Drosophila melanogaster gene (Mad) implicated in a transforming growth factor-beta (TGF-beta)-like signaling pathway. Potentially inactivating mutations in DPC4 were identified in six of 27 pancreatic carcinomas that did not have homozygous deletions at 18q21.1. These results identify DPC4 as a candidate tumor suppressor gene whose inactivation may play a role in pancreatic and possibly other human cancers.
                Bookmark

                Author and article information

                Journal
                Breast Cancer Res
                Breast Cancer Research
                BioMed Central (London )
                1465-5411
                1465-542X
                2000
                21 February 2000
                : 2
                : 2
                : 107-115
                Affiliations
                [1 ]NYU-Mount Sinai School of Medicine, New York, New York, USA.
                Article
                bcr42
                10.1186/bcr42
                139432
                11250700
                85aec787-cd95-4f95-99df-44b5c7d72ddc
                Copyright © 2000 Current Science Ltd
                History
                : 20 December 1999
                : 6 January 2000
                : 25 January 2000
                : 26 January 2000
                Categories
                Review

                Oncology & Radiotherapy
                breast cancer,transforming growth factor (tgf)-β,tumor suppressor,growth inhibition,smad proteins

                Comments

                Comment on this article